Sixty nosocomial infections caused by Pseudomonas aeruginosa and Acinetobacter baumannii resistant to aminoglycosides, cephalosporins, quinolones, penicillins, monobactams, and imipenem were treated with colistin (one patient had two infections that are included as two different cases). The infections were pneumonia (33% of patients), urinary tract infection (20%), primary bloodstream infection (15%), central nervous system infection (8%), peritonitis (7%), catheter-related infection (7%), and otitis media (2%). A good outcome occurred for 35 patients (58%), and three patients died within the first 48 hours of treatment. The poorest results were observed in cases of pneumonia: only five (25%) of 20 had a good outcome. A good outcome occurred for four of five patients with central nervous system infections, although no intrathecal treatment was given. The main adverse effect of treatment was renal failure; 27% of patients with initially normal renal function had renal failure, and renal function worsened in 58% of patients with abnormal baseline creatinine levels. Colistin may be a good therapeutic option for the treatment of severe infections caused by multidrugresistant P. aeruginosa and A. baumannii.
The emergence of multidrug-resistant gram-negative organlittle activity has been demonstrated against Serratia species, Providencia species, and Proteus mirabilis [5, 6] . isms causing nosocomial infections is a growing problem worldwide [1, 2] . In our hospital, Acinetobacter baumannii and All the multidrug-resistant isolates of P. aeruginosa and A. baumannii in our hospital were susceptible in vitro to colisPseudomonas aeruginosa resistant to all commercially available antimicrobial drugs have been important causes of infectin. The objective of this study was to evaluate the use of colistin in the treatment of infections caused by these multitions acquired mainly in intensive care units [3, 4] . Hospital das ClıB nicas is a 2,200-bed tertiary care hospital attached to drug-resistant microorganisms. the University of São Paulo (São Paulo, Brazil). Infection due to multidrug-resistant A. baumannii has been a problem since Methods 1993 when an outbreak occurred. All isolates were one clone, and the outbreak was initially controlled; however, clusters of Patients with infections caused by multidrug-resistant P. aeruginosa or A. baumannii who were hospitalized during the cases have been occurring since then [3] . Multidrug-resistant P. aeruginosa infections have been investigated in our hospital; period from January 1993 to December 1994 were treated with intravenous colistin (colistimethate sodium, Parke-Davis, Morfour different typing methods have revealed that these infections are caused by multiple clones (authors' unpublished data).
ris Plains, NJ; or colistin sodium methane sulfonate, Bellon, Rhône-Poulenc Rorer, Neuilly sur Seine, France). Colistin, a polymyxin, was used from the 1960s to the early 1980s. Because of toxicity considerations (mainly nephrotoxicAll infections were diagnosed according to the criteria of the Centers for Disease Control and Prevention [8] . On the ity, neuromuscular blockade, and neurotoxicity), its systemic use has been all but abandoned [5, 6] . The mechanism of action basis of their etiologies, the cases were considered confirmed or probable. A confirmed case was defined as a nosocomial of colistin is not very clear; however, it is believed that its bactericidal activity is due to a detergent effect on the cell infection with a culture of a specimen obtained from a usually sterile site (e.g., blood or CSF) that was positive for P. aerugimembrane [6, 7] . In vitro colistin has shown excellent activity against a variety of gram-negative rods including those resistant nosa or A. baumannii. A probable case was defined as an infection whose etiology could not be confirmed because the to other classes of antimicrobials (penicillins, cephalosporins, quinolones, aminoglycosides, and carbapenems), although very positive culture was of a specimen from a usually nonsterile site for which there was no evidence of another cause. Identification of P. aeruginosa and A. baumannii was performed by using classic biochemical methods [9, 10] . Susceptibility testing was done according to an automated method (Oxoid, Basingstoke, Hants, England), and isolates were con-(36%); ceftazidime, 16 (29%); quinolones, 16 (29%); and thirdgeneration cephalosporins, 15 (27%). sidered susceptible if the inhibition zone was §11 mm.
Only infections for which there was no other therapeutic A good outcome occurred in 35 (58%) of the cases. Of the confirmed cases, 28 (67%) had a good outcome, and of the option were treated with colistin. Patients were evaluated at the beginning of treatment for the following data: age, gender, probable cases, seven (39%) had a good outcome. The infections and their outcomes are shown in table 1. In the cases identity of infectious agent, and severity of clinical condition according to the APACHE (Acute Physiological and Chronic with a good outcome, fever lasted for a mean duration { SD of 5.5 { 5.8 days (range, 0 -21 days). Follow-up cultures of Health Evaluation) II scoring system [11] . Patients were followed up until the end of the treatment for outcome that was specimens from the original positive site were performed in 29 cases; 27 (93%) of these cultures were negative. Death considered improved or worsened based on clinical criteria, the evaluation of the attending physician, and adverse events. occurred in 22 cases (37%); three of the patients died within the first 48 hours of treatment. The patients were treated with 2.5 to 5.0 mg of colistin/kg daily up to a maximum dose of 300 mg, which was divided
The mean daily dose of colistin { SD was 152.8 { 62.8 mg (range, 60 -300 mg); the mean duration of treatment { SD in two or three doses intravenously. When the patients presented with renal failure, the daily dose was adjusted as follows: was 12.6 { 6.8 days (range, 2 -34 days). The mean duration of treatment { SD for the surviving patients was 14.0 { 5.1 serum creatinine level from 1.3 to 1.5 mg/dL, daily dose of 2.5 to 5.0 mg/kg; 1.6 to 2.5 mg/dL, 2.5 mg/kg; and ú2.5 days (range, 5 -25 days). The mean baseline serum creatinine level { SD was 1.5 { mg/dL, 1.0 to 1.5 mg/kg.
The isolates were resistant to the following antimicrobials 1.5 mg/dL (range, 0.1 -9.1 mg/dL), and 19 (32%) of the patients presented with renal failure defined as a creatinine level on the basis of the MICs: ticarcillin and piperacillin (MIC, ú64 mg/mL), ceftazidime (MIC, §64 mg/mL), aztreonam of ú1.5 mg/dL or a urea level of ú50 mg/dL. Eleven (27%) of the 41 patients with normal renal function at the initial (MIC, §32 mg/mL), amikacin (MIC, §32 mg/mL), gentamicin (MIC, §8 mg/mL), ciprofloxacin (MIC, §4 mg/mL), and imievaluation presented with worsening renal function during treatment (mean increase in creatinine level { SD, 0.9 { 0.6 penem (MIC, ú8 mg/mL). The MIC breakpoints for susceptibility according to the National Committee for Clinical Laboramg/dL; range, 0.3 -2.4 mg/dL). Follow-up was possible for six of these 11 patients, and the creatinine levels became normal tory Standards [12] are as follows: 64 mg of ticarcillin/mL or 64 mg of piperacillin/mL, P. aeruginosa; 16 mg of piperacillin/ in three within 1 month after the end of treatment. Of 19 patients with abnormal baseline creatinine levels, 11 (58%) had mL or 16 mg of ticarcillin/mL, A. baumannii; 8 mg of ceftazidime/mL, both microorganisms; 8 mg of aztreonam/mL, both worsening renal function during treatment (mean increase in creatinine level { SD, 1.5 { 1.4 mg/dL; range, 0.1 -4.0 microorganisms; 16 mg of amikacin/mL, both microorganisms; 4 mg of gentamicin/mL, both microorganisms; 1 mg of cimg/dL). Nephrotoxicity did not cause discontinuation of treatment. No neuromuscular disorders were observed. profloxacin/mL, both microorganisms; and 4 mg of imipenem/ mL, both microorganisms.
Discussion
The emergence of multidrug-resistant P. aeruginosa and Results A. baumannii causing nosocomial infections poses a very serious therapeutic problem in Brazil as there are no commercially Sixty infections in 59 patients were treated with colistin (one patient had two infections that are included as two different available alternatives for treatment. Until the early 1980s, colistin was used for treating infections caused by gram-negative cases); 21 (35%) were caused by P. aeruginosa, and 39 (65%) were caused by A. baumannii. The mean age { SD of the rods. The use of colistin was dropped when second-and thirdgeneration cephalosporins became available, mainly because of patients was 42.1 { 21.4 years (range, 2 -85 years), and 39 (65%) were male. The specimens from which the microorgantoxicity [5] . Ticarcillin was commercialized only in the 1990s. Colistin is not available in Brazil, although it is an approved isms were isolated are listed in table 1.
The etiology of 42 infections (70%) was confirmed, and 18 drug (thus allowing importation from other countries).
Colistin was reported as a new agent in 1952 and was shown cases (30%) were probable.
The underlying diseases in the 59 patients are listed in table to be polymyxin E, belonging to the polymyxins (a polypeptide antibiotic group discovered in 1947 -1948). Polymyxin E is 2. The mean APACHE II score { SD was 13.1 { 7.0 (range, 2 -34). Thirty-one infections (52%) occurred in intensive care sulfomethylated, obliterating its cationic nature and rendering it ineffective as an antibiotic. The sulfomethyl polymyxin must units, 8 (13%) in transplant units, and 21 (35%) in medical or surgical wards. The mean hospital stay before infection { SD be hydrolyzed to release the active free base, and this release occurs at body temperature and at physiological pH in aqueous was 38.4 { 37.1 days (range, 0 -237 days). Fifty-six infections (93%) had been previously treated with other antimicrobials:
systems. The sulfomethylated form of the drug is called colistimethate sodium or colistin sodium methane sulfonate [13] . The imipenem, 30 (54%) of the treated cases; aminoglycosides, 20
04-06-99 07:38:07 cida UC: CID antibacterial action of colistin is poorly understood, but the other available drugs as well as infections due to other gramnegative bacilli. These infections included septicemia and uribacterial cell membrane is disrupted by the binding of the drug nary tract, wound, and respiratory tract infections [16 -20] . to phospholipids, leading to the death of the organism. The
There are also studies reporting good results of colistin treatdrug binds to acidic phospholipids in mammalian tissue, where ment of children and newborns [21, 22] . In our study, colistin it has no antibacterial activity [7] but may account for the was used only in cases in which there were no therapeutic persistent detectable levels of the free form that might be slowly alternatives. The patients treated were mostly from intensive released from binding sites. Colistin has no effect against gramcare units, which are mostly affected by multidrug-resistant positive bacteria, has an insignificant antifungal effect, and is organisms, and were severely ill as can be seen by their undereffective against gram-negative bacilli (including P. aerugilying conditions and APACHE II scores. A good outcome nosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter occurred in 35 (58%) of 60 cases. Three patients died within species, Salmonella species, Shigella species, Vibrio species, the first 48 hours of treatment, and these patients' treatments Pasteurella species, Haemophilus species, and Bordetella specannot really be considered as failures. cies); Proteus species, Providencia species, and most Serratia
The infection associated with the poorest results was pneuisolates are resistant to colistin [14, 15] . monia, for which 15 of 20 treatments failed. This occurrence In the past (1960s and 1970s), colistimethate sodium was cannot be explained by the fact that in most of these cases used to treat infections caused by P. aeruginosa resistant to the etiologies were probable and not confirmed, because four of five confirmed cases had a bad outcome. Results were good for a variety of different infections, and surprisingly, four of tors [22] who reported good results of colistin treatment sugAbdominal surgery 10 (17) gest that further studies are needed to clarify this issue. A Hematologic malignancy 7 (12) possible explanation is the improvement of penetration with Transplantation (bone marrow, kidney, or liver) 7 (12) inflammation. Burn 6 (11) Toxicity is an important concern with colistin, and it has Tetanus 5 (8) Hepatic cirrhosis 5 (8) never been a first choice for treatment of infections due to gramTrauma 3 (5) negative bacteria because of this concern, although toxicity was Chagas' disease 2 (3) not recognized at first [13] . Nephrotoxicity is the most im- 
